Israel’s VBL Therapeutics hit with CMC delays in ovarian cancer study; Novo Holdings buys out diagnostics player BBI

VBL Therapeutics has hit a roadblock in its Phase III study for platinum-resistant ovarian cancer.

Batches of the VB-111 compound being evaluated in the study are still being reviewed by the FDA’s CMC group, the company announced Tuesday, with regulators trying to compare VB-111 manufacturing between...

Click to view original post